Sanofi Analyst Price Targets - Benzinga

Sanofi SA

SNYNASDAQ

Trade with Public

Trade with Public

$44.82

-0.02-0.04%

가까이에: Aug 27, 5:00 PM EST

$44.90

0.060.13%

프리마켓: 5:44 AM EST

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 옵션 주식 보고서

Sanofi Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sanofi (SNY).

Price Target Range — 4 Quarters

Analyst Consensus — 8 Analysts

4Buy

4Hold

Consensus RatingNeutral# Analysts8Avg. Consensus PT$61Upside to Avg. PT+35.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jan 16, 2026	UBS	Matthew Weston	Downgrade	Buy→Neutral	—
Jan 6, 2026	Barclays	—	Downgrade	Overweight→Equal-Weight	—
Dec 9, 2025	Guggenheim	Seamus Fernandez	Downgrade	Buy→Neutral	—
Dec 8, 2025	JP Morgan	Richard Vosser	Downgrade	Overweight→Neutral	—
Oct 27, 2025	Jefferies	—	Assumes	Buy	—
Sep 8, 2025	Morgan Stanley	Mark Purcell	Upgrade	Equal-Weight→Overweight	$56→$58
Sep 2, 2025	Deutsche Bank	Emmanuel Papadakis	Upgrade	Hold→Buy	—
Aug 8, 2025	JP Morgan	Richard Vosser	Upgrade	Neutral→Overweight	—
Mar 21, 2025	Goldman Sachs	James Quigley	Initiate	Neutral	$65
Jul 26, 2024	Argus Research	Jasper Hellweg	PT Raise	Buy	$55→$60
Jan 23, 2024	Morgan Stanley	Mark Purcell	Initiate	Equal-Weight	$55

More with Benzinga EdgeGet Access

Analyst Ratings News

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.

Vandana Singh

Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.

Vandana Singh

March Inflation Set For Biggest Jump Since June 2022 — When CPI Spikes, These Stocks Fall

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9% monthly CPI surge — the steepest since June 2022.

Piero Cingari

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.

Vandana Singh

Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism

Dianthus Therapeutics shares jump after early success in a Phase 3 trial for CIDP treatment claseprubart, signaling potential progress toward approval.

Vandana Singh

Why Is Nektar Therapeutics Stock Gaining Wednesday?

Nektar Therapeutics stock surged after positive data showed sustained and deepening disease control with its eczema therapy.

Vandana Singh